First Participants Dosed in Innovative AV-1980R Alzheimer's Vaccine Study

Overview of TAURUS-1980 Study

The Institute for Molecular Medicine (IMM) and Nuravax have recently launched an exciting new phase in Alzheimer's research. This involves their Phase 1 clinical trial (TAURUS-1980) focusing on AV-1980R, an investigational vaccine designed to target tau pathology, which is crucial in the development of Alzheimer's disease. On October 7, 2026, the dosages for the first four participants were successfully administered, marking a significant milestone in the quest for Alzheimer’s prevention.

Understanding AV-1980R

AV-1980R is an innovative approach utilizing a recombinant protein vaccine developed on IMM’s advanced MultiTEP platform. This vaccine aims to elicit robust immune responses by generating helper T-cell activity, which subsequently promotes B-cell production of antibodies against tau. The tau protein, when misfolded, accumulates in the brains of Alzheimer's patients, leading to neurodegeneration. Therefore, the goal of AV-1980R is to stimulate the body’s immune system to combat this pathological accumulation before cognitive symptoms can manifest.

Study Design and Participants

The TAURUS-1980 study is characterized as a multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation trial. The participants in this study are up to 48 cognitively healthy individuals aged between 65 and 80 who exhibit biomarkers indicating amyloid pathology, which is associated with Alzheimer’s risk. Within three ascending-dose cohorts (20, 60, and 180 micrograms), individuals will receive intramuscular injections of either AV-1980R or a placebo at specific intervals, and their progress will be monitored for safety and immune response over 58 weeks.

Study Goals

The primary focus of TAURUS-1980 is to assess the safety and tolerability of the vaccine. Secondary objectives include evaluating the induced anti-tau antibody and T-cell responses. Besides, exploratory assessments will monitor plasma Alzheimer’s disease biomarkers, tau PET imaging, and cognitive measures. The insights gathered from this trial will guide the design of future studies aiming to evaluate the efficacy of AV-1980R in preventing Alzheimer's disease.

Expert Insights

Dr. Lon S. Schneider, a leading investigator from the Keck School of Medicine of USC, emphasized the significance of understanding whether active tau vaccination can be conducted safely and whether it generates the desired immune response prior to the onset of cognitive symptoms. This clinical inquiry could pave the way for groundbreaking advancements in preventing the progression from preclinical Alzheimer's to clinical symptoms.

Supporting Institutions

The TAURUS-1980 trial is supported by the National Institute on Aging (NIA), which is part of the National Institutes of Health (NIH), solidifying its importance within the scientific community. The substantial funding of $24.5 million through grant program AG092924 underscores the commitment to advancing Alzheimer's research.

Conclusion

The initiation of this innovative study represents a hopeful step toward developing an effective immunotherapy for Alzheimer's disease. By closely monitoring the outcomes of this trial, researchers aim to set the foundation for future larger studies that could ultimately assess the impact of AV-1980R on patients' clinical and biomarker progression. Significant strides in Alzheimer's research are essential, particularly considering the increasing global prevalence of this neurodegenerative disease. As further results emerge, the academic and medical communities remain optimistic about the potential of immunotherapy approaches like AV-1980R to reshape the landscape of Alzheimer's treatment.